Article Details
Retrieved on: 2022-10-04 16:50:32
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
TALZENNA® first PARP inhibitor to demonstrate clinical benefit in combination with XTANDI ® in metastatic castration-resistant prostate cancer ...
Article found on: www.pfizer.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here